product
153904The Hard Sellhttps://www.gandhi.com.mx/the-hard-sell-3/phttps://gandhi.vtexassets.com/arquivos/ids/1773363/faae4f0f-c219-4236-b6ce-efc3ca17b47b.jpg?v=638338916913400000334334MXNPan MacmillanInStock/Audiolibros/<p>Soon to be the major motion picture <em>Pain Hustlers</em> starring Emily Blunt and Chris Evans streaming on Netflix</p><p>A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading <em>The Hard Sell</em> is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me Im wrong. - Patrick Radden Keefe, <em>The New York Times</em></p><p>In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.</p><p>Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the governments fight to hold the drug industry accountable in the spread of addictive opioids.</p><p>With colourful characters and true suspense, <em>The Hard Sell</em> lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream in the doctors office . . .</p>...154136The Hard Sell334334https://www.gandhi.com.mx/the-hard-sell-3/phttps://gandhi.vtexassets.com/arquivos/ids/1773363/faae4f0f-c219-4236-b6ce-efc3ca17b47b.jpg?v=638338916913400000InStockMXN99999DIAudiolibro20239781035009725_W3siaWQiOiIwZjcwZjRkNS1lMGQ2LTQzY2UtYTc0Yi1mOWU1OGZlY2Q1MzEiLCJsaXN0UHJpY2UiOjMzOCwiZGlzY291bnQiOjAsInNlbGxpbmdQcmljZSI6MzM4LCJpbmNsdWRlc1RheCI6dHJ1ZSwicHJpY2VUeXBlIjoiV2hvbGVzYWxlIiwiY3VycmVuY3kiOiJNWE4iLCJmcm9tIjoiMjAyNS0wMS0wOFQwNTowMDowMFoiLCJyZWdpb24iOiJNWCIsImlzUHJlb3JkZXIiOmZhbHNlLCJpc0VsaWdpYmxlRm9yQ3JlZGl0VHJpYWwiOnRydWUsImNyZWRpdFB1cmNoYXNlUHJpY2UiOjF9XQ==9781035009725_<p><strong>A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading <em>The Hard Sell</em> is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me Im wrong. - Patrick Radden Keefe, author of <em>Empire of Pain</em></strong></p><p>In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.</p><p>Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was a niche product, approved only for cancer patients in dire condition. So he recruited an ambitious, persuasive team, who employed a variety of deceptive techniques, from zeroing in on suspect doctors, to falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation.</p><p>That is, until insiders reached their breaking point and blew the whistle. They sparked a sprawling investigation that would lead to a dramatic courtroom battle, breaking new ground in the governments fight to hold the drug industry accountable in the spread of addictive opioids.</p><p>With colourful characters and true suspense, <em>The Hard Sell</em> lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream in the doctors office.</p>(*_*)9781035009725_<p>Soon to be the major motion picture <em>Pain Hustlers</em> starring Emily Blunt and Chris Evans streaming on Netflix</p><p>A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading <em>The Hard Sell</em> is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me Im wrong. - Patrick Radden Keefe, <em>The New York Times</em></p><p>In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.</p><p>Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the governments fight to hold the drug industry accountable in the spread of addictive opioids.</p><p>With colourful characters and true suspense, <em>The Hard Sell</em> lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream in the doctors office . . .</p>...9781035009725_Pan Macmillanaudiolibro_8e82a1eb-dad3-3b6a-a08f-655df3713adc_9781035009725;9781035009725_9781035009725Evan HughesInglésMéxicoNoMINUTE2023-01-19T00:00:00+00:00Pan Macmillan